Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch BioSpaceNovo Nordisk's oral Wegovy has a few months' head start on Eli Lilly's newly approved pill.CommercialMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. CommercialMetabolic & GLP-1Read full story Post navigation Previous: Senju launches first-in-class dry eye disease drug in JapanNext: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026